MediWound Ltd.

A topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and/or full-thickness thermal burns without harming viable tissue. Approved in over 40 countries, including the United States, European Union, and Japan. Recently, the FDA approved NexoBrid for use in pediatric patients.

A bioactive, multimodal debridement therapy for the treatment of chronic and other hard-to-heal wounds, currently in advanced stages of clinical development. It is a concentrate of proteolytic enzymes enriched with bromelain for topical applications. The Phase 3 study for EscharEx is set to commence in the second half of 2024.

An innovative topical biological drug currently in development to address the treatment needs of low-risk Basal Cell Carcinoma (BCC). In a Phase I/II trial, MW005 was shown to be safe and effective for BCC treatment, with positive initial data indicating complete histological clearance of target lesions.

Chief Executive Officer

Founder

Chief R&D Officer

Chief Operating Officer & Chief Commercial Officer

Chief Medical Officer

Chief Financial Officer

Executive Vice President & General Counsel

Executive Vice President of Strategy & Corporate Development

VP Plant Manager

VP Clinical Affairs

VP Research & Development

VP European Operations

VP Regulatory Affairs

Executive Director of Quality Assurance

Executive Director of Manufacturing Science and Technology

Medical Director

Chairman of the Board of Directors

Board Member

Board Member

Board Member

Board Member

Board Member

Board Member